Learn More
BACKGROUND Etravirine, a nonnucleoside reverse transcriptase inhibitor, was provided through an international early access program (EAP) prior to regulatory approval. METHODS The Phase III,(More)
OBJECTIVES Three studies were conducted to assess the pharmacokinetics, methods of administration and ease of swallowability of etravirine tablets. METHODS Two randomized studies in healthy adults(More)
  • 1